Workstream Type: Policy Comments

Formal responses to government RFIs

  • Medicare Part B Premium Dynamics Explained

  • Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs

  • Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle

  • After 4 Years of Trump, Medicare and Medicaid Badly Need Attention

  • CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs

  • CMS Announces Delay of MCIT Final Rule

  • Research on the current state of US drug pricing and its effects

  • Who Is Sowing Seeds of Confusion About The QALY?